Agonist and antagonist-dependent internalization of the human vasopressin V2 receptor

被引:35
|
作者
Pfeiffer, R
Kirsch, J
Fahrenholz, F
机构
[1] Univ Mainz, Inst Biochem, D-55099 Mainz, Germany
[2] Max Planck Inst Hirnforsch, D-60528 Frankfurt, Germany
关键词
vasopressin; human V-2 receptor; receptor internalization; desensitization; antagonists;
D O I
10.1006/excr.1998.4159
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this report we demonstrate that in HEK293 cells stably expressing the human V-2 vasopressin receptor, ligand-induced internalization of the hormone receptor occurs via the clathrin-dependent pathway. Studies of receptor trafficking either by direct visualization of the V-2 receptor by confocal microscopy or binding experiments show a rapid internalization (half-time 6-7 min), Blocking of the clathrin-dependent pathway by hypertonic sucrose increased vasopressin-induced cellular cAMP production and decreased the desensitization of the V-2 receptor-adenylyl cyclase system. Thus, internalization appears to be a major regulatory mechanism terminating vasopressin action in HEK293 cells. Two antagonists of the vasopressin V-2 receptor exerted different effects on receptor internalization, as determined by confocal fluorescence microscopy, The nonpeptidic antagonist OPC31260 did not induce any visible receptor internalization, whereas the peptidic antagonist d(CH2)(5)[D-Tyr(Et)(2),Val(4),Lys(8), Tyr-NH29]VP induced a slow but substantial receptor internalization. These results suggest that long-term treatment with peptidic V-2 receptor antagonists might lead to desensitization. (C) 1998 Academic Press.
引用
收藏
页码:327 / 339
页数:13
相关论文
共 50 条
  • [21] Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist
    Gattone, VH
    Wang, XF
    Harris, PC
    Torres, VE
    NATURE MEDICINE, 2003, 9 (10) : 1323 - 1326
  • [22] Use of Oral Vasopressin V2 Receptor Antagonist for Hyponatremia in Acute Brain Injury
    Jeon, Sang-Beom
    Choi, H. Alex
    Lesch, Christine
    Kim, Myung Chun
    Badjatia, Neeraj
    Claassen, Jan
    Mayer, Stephan A.
    Lee, Kiwon
    EUROPEAN NEUROLOGY, 2013, 70 (3-4) : 142 - 148
  • [23] LIXIVAPTAN Vasopressin V2 Receptor Antagonist Treatment of Heart Failure Treatment of Hyponatremia
    Daifallah, S.
    Zmily, H. D.
    Alqwasmi, A. H.
    Zayed, H.
    Ghali, J. K.
    DRUGS OF THE FUTURE, 2011, 36 (05) : 359 - 370
  • [24] Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist
    Vincent H Gattone
    Xiaofang Wang
    Peter C Harris
    Vicente E Torres
    Nature Medicine, 2003, 9 : 1323 - 1326
  • [25] Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist
    Gunnet, JW
    Matthews, JM
    Maryanoff, BE
    de Garavilla, L
    Andrade-Gordon, P
    Damiano, B
    Hageman, W
    Look, R
    Stahle, P
    Streeter, AJ
    Wines, PG
    Demarest, KT
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (04) : 320 - 326
  • [26] OPC-31260 - A NONPEPTIDE ORALLY ACTIVE V2 VASOPRESSIN RECEPTOR ANTAGONIST
    BURRELL, LM
    PHILLIPS, PA
    STEPHENSON, J
    RISVANIS, J
    JOHNSTON, CI
    JOURNAL OF ENDOCRINOLOGY, 1992, 135 : P56 - P56
  • [27] Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V(1A) and V2 receptor antagonist
    Tahara A.
    Saito M.
    Sugimoto T.
    Tomura Y.
    Wada K.
    Kusayama T.
    Tsukada J.
    Ishii N.
    Yatsu T.
    Uchida W.
    Tanaka A.
    Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 357 (1) : 63 - 69
  • [28] Pharmacological characterization of YMO87, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist
    Tahara, A
    Saito, M
    Sugimoto, T
    Tomura, Y
    Wada, K
    Kusayama, T
    Tsukada, J
    Ishii, N
    Yatsu, T
    Uchida, W
    Tanaka, A
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (01) : 63 - 69
  • [29] Vasopressin V2 Receptor/Bioligand Interactions
    Cezary Czaplewski
    Rajmund Kaźmierkiewicz
    Jerzy Ciarkowski
    Letters in Peptide Science, 1998, 5 : 333 - 335
  • [30] Degradation of V2 vasopressin receptor mutants
    Schwieger, I
    Lautz, K
    Wiesner, B
    Hermosilla, R
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 372 : 33 - 33